We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+4.75%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$410M
AUM Growth
+$3.58M
Cap. Flow
-$16.8M
Cap. Flow %
-4.11%
Top 10 Hldgs %
72.55%
Holding
40
New
17
Increased
1
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$38.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.8M
3
AGN.PRA
Allergan plc
AGN.PRA
+$36.2M
4
TSRO
TESARO, Inc.
TSRO
+$27.2M
5
EHC icon
Encompass Health
EHC
+$20.6M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$35.2M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$34.5M
3
LLY icon
Eli Lilly
LLY
+$34.2M
4
ESRX
Express Scripts Holding Company
ESRX
+$33.1M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Sector Composition

Rank Sector Weight
1 Healthcare 80.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
26
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.57M 0.63%
463,297
-105,900
-19% -$547K
SIEN
27
DELISTED
Sientra, Inc.
SIEN
$2.01M 0.49%
+13,041
New +$1.53M
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$348M
$1.39M 0.34%
195,481
-15,450
-7% -$70.6K
ABT icon
29
Abbott
ABT
$180B
– –
-450,700
Closed -$21.9M
CVS icon
30
CVS Health
CVS
$137B
– –
-226,600
Closed -$18.2M
DVA icon
31
DaVita
DVA
$15.1B
– –
-258,800
Closed -$16.8M
GILD icon
32
Gilead Sciences
GILD
$161B
– –
-373,800
Closed -$26.5M
LLY icon
33
Eli Lilly
LLY
$1.07T
– –
-415,200
Closed -$34.2M
NBIX icon
34
Neurocrine Biosciences
NBIX
$17.7B
– –
-749,200
Closed -$34.5M
TVTX icon
35
Travere Therapeutics
TVTX
$5.33B
– –
-246,289
Closed -$4.78M
VTRS icon
36
Viatris
VTRS
$20.1B
– –
-907,100
Closed -$35.2M
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,082,100
Closed -$4.97M
FWP
38
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-93,214
Closed -$13.3M
LPNT
39
DELISTED
LifePoint Health, Inc.
LPNT
– –
-133,700
Closed -$8.98M
NDRM
40
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-357,400
Closed -$10.7M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Senzar Asset Management held 40 positions worth $410M, up 0.88% from $406M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Senzar Asset Management withdrew a net $16.8M in Q3 2017, closing 12 positions and reducing 10 holdings. Its most notable exit was Viatris, an estimated $35.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 90% a quarter earlier.

Against the trend, Senzar Asset Management opened a new position in Sanofi worth $39.7M.

  • Senzar Asset Management's largest Q3 2017 buy was Sanofi: 797,486 shares worth $39.7M.
  • Senzar Asset Management added most to Alder Biopharmaceuticals in Q3 2017, an estimated $870K increase.
  • Senzar Asset Management's biggest Q3 2017 reduction was Express Scripts Holding Company, cutting an estimated $33.1M.
  • Senzar Asset Management fully exited Viatris in Q3 2017, selling an estimated $35.2M.
  • Senzar Asset Management's ten largest holdings make up 73% of its $410M portfolio in Q3 2017.
  • Senzar Asset Management opened 17 new positions and closed 12 in Q3 2017.
  • Senzar Asset Management's portfolio value rose 0.88% quarter-over-quarter to $410M.

Based on Senzar Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.